Eurofins Genomics adopts Olink® technology to advance proteomics research and accelerate precision medicine programs
13 September 2023 - 1:00AM
Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced the
collaboration with Eurofins Genomics to bolster its offerings in
the fields of research, population health, and regulated clinical
trials through the application of Olink technology.
The Olink platform represents the cutting edge in proteomics
technology, delivering exceptional sensitivity and specificity for
protein biomarker measurement. Olink Explore HT is the company's
latest solution for high-throughput proteomics, allowing scientists
to accurately measure over 5,300 proteins using only 2µl of sample.
Eurofins Genomics joins a worldwide network of service providers
that have adopted the Olink platform. Eurofins Genomics will extend
its multi-omic offering to facilitate the discovery and validation
of protein biomarkers across biological pathways and sample
matrices through the use of the Olink plantform
Jon Heimer, CEO of Olink, stated, “We are immensely pleased to
see the Olink Explore platform being utilised by Eurofins Genomics,
one of the world’s leading multiomic service providers, that
contribute to a safer and healthier world by providing their
customers with innovative and high-quality services. With their
extensive presence in both the pharma and population health spaces,
Eurofins Genomics will apply Olink technology across a broad
spectrum of new therapeutic research fields to improve
understanding of the development, progression, and outcome of
disease.”
Eurofins Genomics will begin applying Olink Explore in three
core areas: expanding proteogenomics to enable deeper insight into
the basis of disease, increasing biomarker discovery for
pre-clinical development and clinical trials, and providing high
throughput proteomic analysis for population-scale health studies.
Eurofins Genomics is a recognized leader in providing multi-omics
services covering genomics, transcriptomics, and epigenomics. Now,
with the addition of Olink technology, Eurofins Genomics will offer
the most powerful proteomic technology available for a more
thorough understanding of the intricate connections between genes,
proteins, and diseases.
Investor contact Jan Medina, CFAVP Investor
Relations & Capital MarketsMobile: +1 617 802
4157jan.medina@olink.com
Media contact Michael B. Gonzales, PhDVice
President, Global Marketing Mobile: +1 415 308
6467michael.gonzales@olink.com
About Olink Holding AB (publ) (Nasdaq: OLK) is
a company dedicated to accelerating proteomics together with the
scientific community, across multiple disease areas to enable new
discoveries and improve the lives of patients. Olink provides a
platform of products and services which are deployed across major
pharmaceutical companies and leading clinical and academic
institutions to deepen the understanding of real-time human biology
and drive 21st century healthcare through actionable and impactful
science. The Company was founded in 2016 and is well established
across Europe, North America and Asia. Olink is headquartered in
Uppsala, Sweden.
About Eurofins Genomics Eurofins Genomics
represents the genomic division within the Eurofins Scientific
Group. With facilities in Europe, the United States and Asia,
Eurofins Genomics is an internationally leading provider of DNA
sequencing and genotyping services, DNA synthesis products and
bioinformatics services for pharma, diagnostics, food, agriculture,
biotechnological and research markets. The European branch is
headquartered in Ebersberg, Germany. For further information,
please visit www.eurofinsgenomics.com
Forward-looking
statementsThis press release
contains express or implied “forward-looking statements” as defined
under the Private Securities Litigation Reform Act of 1995 that are
based on management’s beliefs and assumptions and on information
currently available to management. All statements contained in this
release other than statements of historical fact are
forward-looking statements. In some cases, you can identify
forward-looking statements by the words “may,” “might,” “will,”
“could,” “would,” “should,” “expect,” “intend,” “seek,” “plan,”
“outlook,” “objective,” “anticipate,” “believe,” “estimate,”
“predict,” “project,” “potential,” “continue,” “currently,
“ongoing” or the negative of these terms or other comparable
terminology, although not all forward-looking statements contain
these words. These statements involve risks, uncertainties and
other factors that may cause actual results, levels of activity,
performance, or achievements to be materially different from the
information expressed or implied by these forward-looking
statements. These risks, uncertainties and other factors are
described under the caption "Risk Factors" in our Form 20-F for the
fiscal year ended December 31, 2022 (Commission file number
001-40277) and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections for the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
Investor contact
Jan Medina, CFA
VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157
jan.medina@olink.com
Media contact
Michael B. Gonzales, PhD
Vice President, Global Marketing
Mobile: +1 415 308 6467
michael.gonzales@olink.com
Olink Holding AB (NASDAQ:OLK)
Historical Stock Chart
From Apr 2024 to May 2024
Olink Holding AB (NASDAQ:OLK)
Historical Stock Chart
From May 2023 to May 2024